Shengxiang Ren

机构：Tongji University, Shanghai Pulmonary Hospital · ORCID：0000-0001-8767-9850

发表论文 367 篇 · 总被引 17188 次 · h-index 61

代表论文

• IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC (2025 · Molecular Cancer · 被引 18)
• Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies (2025 · Biological Procedures Online · 被引 11)
• SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade (2024 · Cancer Immunology Immunotherapy · 被引 9)
• Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial (2025 · Signal Transduction and Targeted Therapy · 被引 7)
• Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting (2024 · Journal of Hematology & Oncology · 被引 7)
• Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone (2025 · Journal of Thoracic Oncology · 被引 5)